These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 10402249)
1. A new tubulin polymerization inhibitor, auristatin PE, induces tumor regression in a human Waldenstrom's macroglobulinemia xenograft model. Mohammad RM; Limvarapuss C; Wall NR; Hamdy N; Beck FW; Pettit GR; Al-Katib A Int J Oncol; 1999 Aug; 15(2):367-72. PubMed ID: 10402249 [TBL] [Abstract][Full Text] [Related]
2. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1. Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595 [TBL] [Abstract][Full Text] [Related]
3. Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma. Mohammad RM; Pettit GR; Almatchy VP; Wall N; Varterasian M; Al-Katib A Anticancer Drugs; 1998 Feb; 9(2):149-56. PubMed ID: 9510501 [TBL] [Abstract][Full Text] [Related]
4. Rituximab, Cyclophosphamide, Dexamethasone (RCD) regimen induces cure in WSU-WM xenograft model and a partial remission in previously treated Waldenstrom's macroglobulinemia patient. Mohammad RM; Aboukameel A; Nabha S; Ibrahim D; Al-Katib A J Drug Target; 2002 Aug; 10(5):405-10. PubMed ID: 12442811 [TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid as a modulator of etoposide in human Waldenstrom's macroglobulinemia xenograft model. Mensah-Osman EJ; Al-Katib AM; Mohammad RM Clin Cancer Res; 2003 Nov; 9(15):5794-7. PubMed ID: 14654565 [TBL] [Abstract][Full Text] [Related]
6. The Wayne State University Waldenstrom's Macroglobulinemia preclinical model for Waldenstrom's macroglobulinemia. Al-Katib AM; Mensah-Osman E; Aboukameel A; Mohammad R Semin Oncol; 2003 Apr; 30(2):313-7. PubMed ID: 12720160 [TBL] [Abstract][Full Text] [Related]
7. Propagation of Waldenström's macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model. al-Katib A; Mohammad R; Hamdan M; Mohamed AN; Dan M; Smith MR Blood; 1993 Jun; 81(11):3034-42. PubMed ID: 8499639 [TBL] [Abstract][Full Text] [Related]
8. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine. Mohammad RM; Limvarapuss C; Hamdy N; Dutcher BS; Beck FW; Wall NR; Al-Katib AM Int J Oncol; 1999 May; 14(5):945-50. PubMed ID: 10200346 [TBL] [Abstract][Full Text] [Related]
9. 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIbeta is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model. Mensah-Osman EJ; Al-Katib AM; Dandashi MH; Mohammad RM Mol Cancer Ther; 2002 Dec; 1(14):1315-20. PubMed ID: 12516964 [TBL] [Abstract][Full Text] [Related]
10. Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents. Mohammad RM; al-Katib A; Pettit GR; Sensenbrenner LL Cancer Res; 1994 Jan; 54(1):165-8. PubMed ID: 8261437 [TBL] [Abstract][Full Text] [Related]
11. Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification. Kalemkerian GP; Ou X; Adil MR; Rosati R; Khoulani MM; Madan SK; Pettit GR Cancer Chemother Pharmacol; 1999; 43(6):507-15. PubMed ID: 10321512 [TBL] [Abstract][Full Text] [Related]
13. Modulation of cIAP-1 by novel antitubulin agents when combined with bryostatin 1 results in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh. Wall NR; Mohammad RM; Nabha SM; Pettit GR; Al-Katib AM Biochem Biophys Res Commun; 1999 Dec; 266(1):76-80. PubMed ID: 10581168 [TBL] [Abstract][Full Text] [Related]
14. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079 [TBL] [Abstract][Full Text] [Related]
15. Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc. Turner T; Jackson WH; Pettit GR; Wells A; Kraft AS Prostate; 1998 Feb; 34(3):175-81. PubMed ID: 9492845 [TBL] [Abstract][Full Text] [Related]
16. Effects of combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines. Nabha SM; Wall NR; Mohammad RM; Pettit GR; Al-Katib AM Anticancer Drugs; 2000 Jun; 11(5):385-92. PubMed ID: 10912955 [TBL] [Abstract][Full Text] [Related]
17. Clonal preservation of human pancreatic cell line derived from primary pancreatic adenocarcinoma. Mohammad RM; Li Y; Mohamed AN; Pettit GR; Adsay V; Vaitkevicius VK; Al-Katib AM; Sarkar FH Pancreas; 1999 Nov; 19(4):353-61. PubMed ID: 10547195 [TBL] [Abstract][Full Text] [Related]
18. Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. Aherne GW; Hardcastle A; Valenti M; Bryant A; Rogers P; Pettit GR; Srirangam JK; Kelland LR Cancer Chemother Pharmacol; 1996; 38(3):225-32. PubMed ID: 8646796 [TBL] [Abstract][Full Text] [Related]